You can Subscribe to our RSS FEED: which delivers brain tumor news and additions to the website via RSS.
Click HERE for details on RSS.
Displaying items 976 to 1000 of about 5880
Next 25
01/09/2020
Survival analysis of patients with glioblastoma treated by long-term administration of temozolomide.
01/08/2020
New book takes a humorous look at brain cancer
Identification of a transient state during the acquisition of temozolomide resistance in glioblastoma.
01/07/2020
DIPG Advocacy Group Announces Congressional Briefing for Pediatric Brain Cancer
01/06/2020
Musella Foundation Awards $250,000 Brain Tumor Research Grant
01/05/2020
Mount Sinai Receives More Than $10 Million in Grant Funding for Brain Tumor Research
01/04/2020
Regorafenib in glioblastoma recurrence: how to deal with conflicting ‘real-life’ experiences?
Cost-effectiveness analysis of the addition of bevacizumab to temozolomide therapy for the treatment of unresected glioblastoma.
Complete radiological response following subtotal resection in three glioblastoma patients under treatment with Tumor Treating Fields.
12/28/2019
Made website more accessable! Click the logo on top right of any page to see!
12/25/2019
A randomized controlled phase III study of VB-111 combined with bevacizumab vs. bevacizumab monotherapy in patients with recurrent glioblastoma (GLOBE).
Similar overall survival with reduced vs. standard dose bevacizumab monotherapy in progressive glioblastoma.
Safety and efficacy of VB-111, an anti-cancer gene-therapy, in patients with recurrent glioblastoma: results of a phase I/II study
12/16/2019
Tumour Treating Fields (TTFields) in combination with lomustine and temozolomide in patients with newly diagnosed glioblastoma.
12/03/2019
Musella Foundation`s Annual Giving Campaign
SNO 2019: The Oncolytic Herpes Virus G47? May Lead to a Potential Cure of Malignant Glioma
12/01/2019
New Italian version of our Brain Tumor Guide for the Newly Diagnosed!
11/28/2019
New videos added to Virtualtrials.com
11/25/2019
DNAtrix Presents Positive Results from the Phase 2 CAPTIVE/KEYNOTE-192 Study of DNX-2401 in Combination with Pembrolizumab for Glioblastoma at the 2019 SNO Annual Meeting
Novocure Announces 43 Presentations on Tumor Treating Fields at 24th Annual Meeting of the Society for Neuro-Oncology
Val-083 for unmethylated GBM
The Conversation
11/19/2019
Publication in Nature Communications Confirms DRD2 as Target of ONC201
RESULTS OF PHASE II CLINICAL TRIAL OF ONCOLYTIC HERPES VIRUS G47? IN PATIENTS WITH GLIOBLASTOMA